Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aligos Therapeutics (ALGS) Treasury Shares (2020 - 2025)

Aligos Therapeutics filings provide 6 years of Treasury Shares readings, the most recent being $76786.0 for Q4 2025.

  • On a quarterly basis, Treasury Shares rose 1523.73% to $76786.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $76786.0, a 1523.73% increase, with the full-year FY2025 number at $76786.0, up 1523.73% from a year prior.
  • Treasury Shares hit $76786.0 in Q4 2025 for Aligos Therapeutics, roughly flat from $76861.0 in the prior quarter.
  • In the past five years, Treasury Shares ranged from a high of $303711.0 in Q1 2021 to a low of $3717.0 in Q2 2022.
  • Median Treasury Shares over the past 5 years was $76823.5 (2025), compared with a mean of $90332.0.
  • Biggest five-year swings in Treasury Shares: tumbled 98.35% in 2022 and later soared 1635.4% in 2025.
  • Aligos Therapeutics' Treasury Shares stood at $89054.0 in 2021, then tumbled by 95.83% to $3717.0 in 2022, then skyrocketed by 44.26% to $5362.0 in 2023, then fell by 11.81% to $4729.0 in 2024, then skyrocketed by 1523.73% to $76786.0 in 2025.
  • The last three reported values for Treasury Shares were $76786.0 (Q4 2025), $76861.0 (Q3 2025), and $17264.0 (Q2 2025) per Business Quant data.